Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation

@article{Hylek2007MajorHA,
  title={Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation},
  author={Elaine Hylek and Carmella Evans-Molina and Carol Shea and Lori Henault and Susan Regan},
  journal={Circulation},
  year={2007},
  volume={115},
  pages={2689-2696}
}
Background— Warfarin is effective in the prevention of stroke in atrial fibrillation but is under used in clinical care. Concerns exist that published rates of hemorrhage may not reflect real-world practice. Few patients ≥80 years of age were enrolled in trials, and studies of prevalent use largely reflect a warfarin-tolerant subset. We sought to define the tolerability of warfarin among an elderly inception cohort with atrial fibrillation. Methods and Results— Consecutive patients who started… 

Figures and Tables from this paper

Rates of hemorrhage during warfarin therapy for atrial fibrillation
TLDR
In this large cohort of older patients with atrial fibrillation, it is found that rates of hemorrhage are highest within the first 30 days of warfarin therapy.
Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation
TLDR
Adherence to anticoagulation is poor in practice and may be modestly improved with NOACs, whereas the benefits of antICOagulation may not outweigh the harms in patients with CHA 2 DS 2‐VASc score 0 or 1.
Complications of Warfarin Therapy in Older Adults: A Review
TLDR
Recent randomized-control trials conducted to identify the risks of bleeding complications of warfarin therapy in the older, frail, vulnerable adult support the net benefit of warFarin anticoagulant therapy for older adults with atrial fibrillation.
Methodological considerations for interpretation of rates of major haemorrhage in studies of anticoagulant therapy for atrial fibrillation.
  • E. Hylek, J. Magnani
  • Medicine
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
  • 2008
TLDR
Two recently published studies contrasting results demonstrate the importance of assessing study design, patient population, selection bias, length of observation, definition of major haemorrhage, specific anticoagulant, quality of antICOagulation control, and use of other risk-modifying therapy in elderly patients initiating warfarin for stroke prevention in AF.
Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation.
TLDR
In the real-world setting apixaban versus warfarin use was associated with less HCRU and lower total all-cause health care costs and costs for bleeding- and stroke-related medical services, but greater pharmacy costs, among elderly NVAF patients.
Factors associated with warfarin discontinuation, including bleeding patterns, in atrial fibrillation patients
TLDR
Risks associated with bleeding events are older age, use of a warfarin-potentiating medication, previous bleeding, and higher CHADS2 scores.
Dabigatran versus warfarin in patients with atrial fibrillation.
TLDR
In patients with atrial fibrillation, dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage.
Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation.
  • W. Bommer
  • Medicine
    Critical pathways in cardiology
  • 2012
TLDR
The advent of alternatives to warfarin for reducing stroke risk in AF patients may improve physicians' ability to offer safe and effective stroke prevention in all AF patients.
The Association Between Bleeding and the Incidence of Warfarin Discontinuation in Patients with Atrial Fibrillation
TLDR
Bleeding was significantly associated with warfarin discontinuation, and thus, the selection of an effective treatment regimen associated with a lower bleeding rate could be a desirable treatment approach.
...
...

References

SHOWING 1-10 OF 65 REFERENCES
Translating the Results of Randomized Trials into Clinical Practice: The Challenge of Warfarin Candidacy Among Hospitalized Elderly Patients With Atrial Fibrillation
TLDR
The findings suggest that many elderly patients at high risk for stroke may not be optimal candidates for anticoagulant therapy and there is a pressing need for alternative stroke prevention strategies for this expanding patient population.
Risk Factors for Complications of Chronic Anticoagulation: A Multicenter Study
TLDR
The incidence of bleeding and thromboembolic complications and related risk factors from a retrospective study of 980 patients followed in five anticoagulation clinics through 1990 are described.
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
TLDR
These findings provide further evidence against the use of lower INR target levels in patients with atrial fibrillation and suggest that anticoagulation that results in an INR of 2.0 or greater reduces not only the frequency of ischemic stroke but also its severity and the risk of death from stroke.
The Risk for and Severity of Bleeding Complications in Elderly Patients Treated with Warfarin
TLDR
This study analyzed data from six anticoagulation clinics to determine whether elderly patients who were receiving warfarin had a higher incidence of complications than similar younger patients who are also receiving warFarin.
Combined Anticoagulant–Antiplatelet Use and Major Bleeding Events in Elderly Atrial Fibrillation Patients
TLDR
Although concerns about increased bleeding risk with combined warfarin-antiplatelet therapy are not unfounded, the risk of bleeding is moderately increased and the decision to use concurrent antiplatelet Therapy appears to be tempered by cardiac and bleeding risk factors.
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.
  • Medicine
    Archives of internal medicine
  • 1994
TLDR
In these five randomized trials warfarin consistently decreased the risk of stroke in patients with atrial fibrillation (a 68% reduction in risk) with virtually no increase in the frequency of major bleeding.
Advanced Age, Anticoagulation Intensity, and Risk for Intracranial Hemorrhage among Patients Taking Warfarin for Atrial Fibrillation
TLDR
A large casecontrol study evaluated the relationship of increasing age and INR to the risk for intracranial hemorrhage among patients with nonvalvular atrial fibrillation and patients receiving anticoagulation who did not develop intracerebral hemorrhage.
...
...